Improve Patient Outcomes
Backed by 20 Years of Clinical Research
Nuwellis Delivers Innovative, Safe, Evidence-Based Solutions
Our clinically validated solution is designed and proven to improve patient outcomes, streamline care, and support hospital efficiency. Nuwellis remains committed to providing precision, reliability, and actionable clinical insights for every patient population.
Clinical Studies
- 60% reduction in heart failure events at 30 days compared to standard intravenous diuretic treatment.¹
- Ultrafiltration delivered meaningful relief.²
- 50% decrease in median hospital admission rates; 69% decrease in hospitalization days.⁴
-
60% reduction in heart failure events at 30 days compared to standard intravenous diuretic treatment.¹
Clinical studies highlight how ultrafiltration can make a positive difference for people living with heart failure. By gently and effectively removing extra fluid, patients experience less discomfort, easier breathing, and a faster path to feeling like themselves again.
Hospitals using this therapy also see fewer returns to the ER, showing its impact on both patient well-being and overall care.
Read the clinical studies:
- Ultrafiltration for Management of Decompensated Heart Failure: A Reappraisal of AVOID-HF
- Extracorporeal Ultrafiltration for Acute Heart Failure
- Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure
- Readmission rate after ultrafiltration in acute decompensated heart failure: a systematic review and meta-analysis
- Ten year real world experience with ultrafiltration for the management of acute decompensated heart failure
- Outcomes of Ultrafiltration in community-based hospitals
-
Ultrafiltration delivered meaningful relief.²
Aquadex by Nuwellis has been studied in more patients than any other ultrafiltration system. Its predictable and precise fluid removal capabilities make it a valuable tool in post-surgical and critical care settings.
Read the clinical studies:
- A Turnkey Order Set for Prevention of Cardia Surgery-Associated Acute Kidney Injury
- Diversifying Aquapheresis in Critical Care: An institutional experience
- The use of simple ultrafiltration technology as a fluid management strategy for high-risk coronary artery bypass grafting surgery
- Fluid Overload and Mortality in Adult Critical Care Patients – A systematic Review and Meta-Analysis of Observational Studies
- Aquapheresis: An Institutional Experience
-
50% decrease in median hospital admission rates; 69% decrease in hospitalization days.⁴
Nuwellis’ Aquadex System delivers a direct solution for outpatient fluid overload management. This clinically proven, FDA-cleared therapy facilitates a seamless transition to outpatient care, a move supported by clinical evidence demonstrating a reduction in hospital readmissions.
Further Reading
- Ultrafiltration can help patients with fluid overload feel better faster by safely removing more excess fluid than IV diuretics alone.⁵
- Ultrafiltration consistently delivers better decongestion and can prevent avoidable rehospitalizations.⁶
- $4,000 in cost savings per patient compared with standard IV diuretic therapy.⁷
-
Ultrafiltration can help patients with fluid overload feel better faster by safely removing more excess fluid than IV diuretics alone.⁵
Ultrafiltration eases symptoms like shortness of breath and swelling, and also lowers the chance of coming back to the hospital for heart failure.
With Nuwellis’s Aquadex system, clinicians have a reliable option when diuretics aren’t enough, providing effective, gentle fluid management that supports both patients and care teams.
Read the clinical studies:
- Ultrafiltration is better than diuretic therapy for volume-overloaded acute heart failure patients
- Readmission rate after ultrafiltration in acute decompensated heart failure: A systematic review and meta-analysis
- Defining the role of ultrafiltration therapy in acute heart failure: A systematic review and meta-analysis
- Efficacy and safety assessment of isolated ultrafiltration compared to intravenous diuretics for acutely decompensated heart failure: a systematic review with meta-analysis
-
Ultrafiltration consistently delivers better decongestion and can prevent avoidable rehospitalizations.⁶
A body of clinical evidence confirms the benefits of Aquadex ultrafiltration therapy over diuretics. Stress on the kidneys from disease or surgery can rapidly escalate to kidney failure and lifetime dependency on dialysis.
Aquadex allows clinicians to gently remove excess fluid and strain on the kidneys while avoiding stressing the kidneys further with nephrotoxic diuretics or more aggressive kidney replacement therapies.
Read the clinical studies:
- Fluid Overload and Precision Net Ultrafiltration in Critically Ill Patients
- A Turnkey Order Set for Prevention of Cardiac Surgery–Associated Acute Kidney Injury
- Adult Cardiac Surgery Associated Acute Kidney Injury: Joint Consensus Report
- Fluid Overload and Precision Net Ultrafiltration in Critically Ill Patients
- Extracorporeal Ultrafiltration for Acute Heart Failure
- Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research
-
$4,000 in cost savings per patient compared with standard IV diuretic therapy.⁷
Although ultrafiltration has a higher upfront cost during hospital admission, this study found that it pays off: by more aggressively reducing fluid overload, ultrafiltration significantly lowers readmission rates and shortens hospital stays over the following 90 days, leading to nearly $4,000 in cost savings per patient compared with standard IV diuretic therapy.
Clinician Perspectives on Aquadex
If we can use ultrafiltration early on, this could help stop the vicious cycle that will start with the use of diuretics…sparing the kidneys and removing fluid at the same time.
Dr. Amir Kazory, MD, FASN, FAHA
University of Florida Health
The value of Aquadex is that it enables the clinician to safely prescribe and adjust the fluid removal rate needed to achieve the desired fluid balance, independent of the kidney’s ability to respond to diuretics.
Dr. David Askenazi MD, MSPH
Children’s of Alabama
Promising Aquadex Therapy for Heart Failure: Updated AVOID-HF Study Analysis
Iribarne A, et al. Ann Thorac Surg. 2014 Oct; 98(4): 1274-80
Sutherland SM, et al. American Journal of Kidney Diseases, vol. 55, no. 2, pp. 316-325, February 2010. Gillespie RS, et al. Pediatric Nephrology, vol. 19, no. 12, pp. 1394-1399, December 2004.
A Prospective Study of Serial Outpatient Aquapheresis Ultrafiltration AT THE CHRIST HOSPITAL IN CINCINNATI, OH
Jain A, Agrawal N, Kazory A. Defining the role of ultrafiltration therapy in acute heart failure: a systematic review and meta-analysis. Heart Fail Rev. 2016 Sep;21(5):611-9. doi: 10.1007/s10741-016-9559-2. PMID: 27154520.
Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research
Costanzo MR, Fonarow GC, Rizzo JA. Ultrafiltration versus diuretics for the treatment of fluid overload in patients with heart failure: a hospital cost analysis. J Med Econ. 2019 Jun;22(6):577-583. doi: 10.1080/13696998.2019.1584109. Epub 2019 Mar 21. PMID: 30775944.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5. PMID: 23747642.